EU regulators approved an expanded indication for Kerendia in heart failure, supported by strong phase III data. The decision strengthens a key growth driver for Bayer and should accelerate product uptake and overall portfolio momentum.
EU regulators approved an expanded indication for Kerendia in heart failure, supported by strong phase III data. The decision strengthens a key growth driver for Bayer and should accelerate product uptake and overall portfolio momentum.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
